Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

SOHO Brazil 2024

A. Zelenetz

ESMO 2024 Summary: Updates in the Treatment of MCL

2024 ESMO Annual Meeting Insights Hub

G. Hess

Lymphoma Hot Topics in 2024: Focus on DLBCL and cHL

Yale Cancer Center

T. Sethi

Tafasitamab + Lenalidomide vs. CIT for Transplant-Ineligible R/R DLB…

Patrizia Mondello

The Relapsed and Refractory MM Patient: When Immune Approaches Are I…

Joseph Mikhael

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Indy Hematology Review

S. Smith

Managing R/R LBCL Patients Treated With Pola-R-CHP in 1L and Are CAR…

University of Colorado Cancer Center

M. Kamdar

Top 5 Lymphoma Abstracts From ASH

Jennifer Amengual

New Updates in Frontline DLBCL

Scripps Health

L. Nastoupil

Considering Alternatives to CAR-T in R/R DLBCL

Julio Chavez

Polatuzumab Vedotin for 1L DLBCL: Results From the POLARIX Trial

Wojciech Jurczak

Tafasitamab/Lenalidomide for DLBCL: Which Patients and What to Expect

Amit Mehta

Treatment Landscape in 1L DLBCL: Polatuzumab Vedotin as SoC

Georg Lenz

Treatment Updates and Management of Non-Hodgkin Lymphomas

Integrity CE

D. Wallace, M. Cortese

CAR T-Cell Therapy in Autoimmune Disorders

Vanderbilt University Medical Center (VUMC)

O. Oluwole

Bispecifics for LBCL: Guidance for Management of Toxicities in the C…

UChicago Medicine

J. Crombie

The Next Frontier of Targeted Therapy in Lymphoma

UChicago Medicine

K. Maddocks

Current Management of DLBCL From Frontline to Relapsed Disease

Dipenkumar Modi

Practice-Changing Updates in DLBCL and HL

Massachusetts General Hospital Cancer Center

J. Erika Haydu